Thus, a new term migrastatic is proposed for drugs directed against all types of migration, the action of which is based on inhibition of acto-myosin contractility and actin polymerization as downstreams effector mechanisms (Solomon et al., 2021) that are common and essential for the motility of all migrating cancer cells (Gandalovičová et al., 2017). This evidence concerns the gene MYH14 and cancer.